Top Page
TYK Medicines, Inc. Class H
(2410)
TYK Medicines, Inc. Class H (2410) vs. iShares MSCI Hong Kong ETF (EWH)
TYK Medicines, Inc. Class H Business Overview & Revenue Model
TYK Medicines, Inc. Class H Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 0.00 | 107.00K | 0.00 | 44.24M |
| Gross Profit | 0.00 | 14.00K | 0.00 | 20.04M |
| EBITDA | -199.38M | -346.03M | -346.80M | -292.22M |
| Net Income | -219.05M | -386.95M | -382.43M | -310.99M |
Balance Sheet | ||||
| Total Assets | 529.30M | 915.69M | 573.14M | 558.36M |
| Cash, Cash Equivalents and Short-Term Investments | 158.31M | 435.46M | 192.83M | 243.49M |
| Total Debt | 120.72M | 176.85M | 1.33B | 82.33M |
| Total Liabilities | 1.57B | 443.13M | 1.45B | 1.06B |
| Stockholders Equity | -1.05B | 469.09M | -973.82M | -505.94M |
Cash Flow | ||||
| Free Cash Flow | -154.55M | -381.87M | -278.20M | -308.23M |
| Operating Cash Flow | -136.28M | -308.25M | -200.94M | -220.05M |
| Investing Cash Flow | -120.14M | -135.86M | 73.01M | -158.16M |
| Financing Cash Flow | 114.65M | 632.08M | 224.00M | 351.14M |
TYK Medicines, Inc. Class H Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | HK$6.86B | 2.21 | 10.84% | 5.80% | -20.64% | -25.39% | |
57 Neutral | HK$8.38B | 135.64 | 6.73% | ― | 23.37% | ― | |
55 Neutral | HK$6.34B | -1.79 | -9.73% | 2.38% | -8.56% | -403.12% | |
54 Neutral | HK$15.79B | -22.61 | -12.74% | ― | -76.58% | -4.90% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$10.80B | 5.89 | 18.28% | ― | 59.70% | 239.97% | |
46 Neutral | HK$4.07B | ― | 153.33% | ― | ― | ― |
TYK Medicines, Inc. Class H Corporate Events
TYK Medicines, Inc. has completed the conversion of 4,608,000 unlisted shares into H shares, with trading of these converted H shares on the Hong Kong Stock Exchange set to begin on March 5, 2026. Following the conversion, all 380,065,818 issued shares of the company are now H shares, simplifying the capital structure and potentially improving liquidity for existing and prospective investors.
The company’s H shares now represent 100% of its share capital, compared with 98.79% before the transaction, eliminating the previous portion of unlisted shares. The board has cautioned shareholders and potential investors to exercise care when dealing in the company’s H shares, underscoring that the change may influence trading dynamics and market perceptions of the stock.
The most recent analyst rating on (HK:2410) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on TYK Medicines, Inc. Class H stock, see the HK:2410 Stock Forecast page.
TYK Medicines, Inc. has agreed to a capital increase in its subsidiary TYK Bio, under which new and existing investors will inject about RMB83.5 million, raising TYK Bio’s registered capital from RMB14.0 million to roughly RMB20.49 million and diluting the parent’s stake from 57.14% to 39.03%. As a result, TYK Bio will cease to be a subsidiary of TYK Medicines, although the funds will be ring‑fenced for operating purposes and restricted from debt repayment to shareholders, non-core expenditures, financial investments, or equity repurchases without subscriber consent.
Because a fund partly owned by chairman and CEO Dr. Wu Yusheng is among the new investors, the deal is treated as a connected transaction under Hong Kong listing rules, but the size of the transaction means it only triggers reporting and announcement obligations, without requiring a shareholder circular or independent shareholder approval. The move provides fresh operating capital for TYK Bio while reducing TYK Medicines’ direct control, potentially shifting the unit’s governance structure and risk profile for minority investors within the framework of the exchange’s related-party transaction safeguards.
The most recent analyst rating on (HK:2410) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on TYK Medicines, Inc. Class H stock, see the HK:2410 Stock Forecast page.
TYK Medicines, Inc., a PRC-incorporated joint stock company listed in Hong Kong, operates through H shares on the Stock Exchange of Hong Kong. Its share capital has comprised both H shares and unlisted shares, enabling participation from both public investors and private venture capital stakeholders.
The company has received approval from the Hong Kong Stock Exchange to list 4,608,000 converted H shares, representing previously unlisted shares held by a single shareholder. Following this conversion, all 380,065,818 shares of the company will be H shares, simplifying the capital structure and completing full circulation of H shares, which may enhance liquidity and accessibility for investors.
The most recent analyst rating on (HK:2410) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on TYK Medicines, Inc. Class H stock, see the HK:2410 Stock Forecast page.
TYK Medicines has announced that China’s National Medical Products Administration has accepted its New Drug Application for Asandeutertinib (TY-9591), a deuterated analog of osimertinib intended as a first-line treatment for adults with locally advanced or metastatic EGFR-mutated non-small cell lung cancer with central nervous system metastases. Backed by Phase I and II clinical data indicating superior intracranial and systemic response rates and clinical benefit compared with existing therapy osimertinib, the filing underscores TYK Medicines’ ambition to strengthen its position in targeted lung cancer treatments, although the company cautions that acceptance of the application is only an administrative step and approval is not guaranteed, highlighting the inherent risks and uncertainties in pharmaceutical development for investors and other stakeholders.
The most recent analyst rating on (HK:2410) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on TYK Medicines, Inc. Class H stock, see the HK:2410 Stock Forecast page.
TYK Medicines announced that its investigational Class 1 new drug Asandeutertinib (TY-9591), a deuterated analog of osimertinib, has been accepted by China’s Center for Drug Evaluation for priority review for use as a first-line treatment for adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) with central nervous system metastases. The decision reflects the drug’s potential to address a significant unmet clinical need in brain metastases from NSCLC, an area where no third-generation EGFR-TKIs have yet been formally approved worldwide for this specific indication and where existing therapies rely on limited retrospective data, with TY-9591’s Phase I and II studies showing promising intracranial and systemic efficacy that could strengthen TYK Medicines’ position in the oncology drug market if ultimately approved.
The most recent analyst rating on (HK:2410) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on TYK Medicines, Inc. Class H stock, see the HK:2410 Stock Forecast page.
TYK Medicines, Inc. has received a filing notice from the China Securities Regulatory Commission approving its H share full circulation application, enabling the conversion of 4,608,000 unlisted domestic shares held by one shareholder into the same number of H shares. Once the conversion is implemented and listing approval is granted by the Hong Kong Stock Exchange, these newly converted H shares will be tradable on the Main Board, potentially enhancing the company’s share liquidity and broadening its investor base, though the detailed implementation plan is still being finalized and remains subject to additional regulatory procedures.
The most recent analyst rating on (HK:2410) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on TYK Medicines, Inc. Class H stock, see the HK:2410 Stock Forecast page.
TYK Medicines, Inc. announced it has been granted a Drug Manufacturing License by the Drug Administration of Zhejiang Province, authorising production via trustee manufacturer Asymchem Life Science (Tianjin) Co., Ltd. through January 2031. The company expects the license to underpin long-term capacity and market expansion and to lay a foundation for subsequent commercial production of its cancer therapies, potentially accelerating the delivery of new treatment options to patients, though it cautions there is no assurance its products will ultimately reach the market.
The most recent analyst rating on (HK:2410) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on TYK Medicines, Inc. Class H stock, see the HK:2410 Stock Forecast page.
TYK Medicines said its investigational Class 1 new drug Asandeutertinib (TY-9591) has been proposed by China’s Center for Drug Evaluation to be included in the national priority review list for first-line treatment of adults with locally advanced or metastatic non-small cell lung cancer, including central nervous system metastases, carrying specific EGFR mutations, underscoring the potential strategic importance of this candidate in the competitive lung cancer therapy market. The board also addressed recent unusual share price and trading volume movements, stating it is unaware of any undisclosed information behind the volatility, and confirmed that the group’s business operations remain normal and stable with core projects progressing as planned, while cautioning investors that there is no assurance the drug will ultimately be successfully developed and marketed.
The most recent analyst rating on (HK:2410) stock is a Hold with a HK$12.50 price target. To see the full list of analyst forecasts on TYK Medicines, Inc. Class H stock, see the HK:2410 Stock Forecast page.